Development of Selective Pyrido[2,3-d]pyrimidin-7(8H)-one-Based Mammalian STE20-Like (MST3/4) Kinase Inhibitors

317 Pharmacy

The authors are grateful to the Structural Genomics Consortium (SGC), a registered charity (no. 1097737) that received funds from Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Genome Canada through Ontario Genomics Institute, Janssen, Merck KGaA, Pfizer, and Takeda. This project received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under Grant 875510. The JU receives support from the European Union's Horizon 2020 research and innovation program, EFPIA, Ontario Institute for Cancer Research, Royal Institution for the Advancement of Learning McGill University, Kungliga Tekniska Hoegskolan, and Diamond Light Source Limited. M R. is grateful for the support by the Dr. Hilmer-Stiftung. A.M. is supported by the German Research Foundation (DFG) Grant 259130777 (SFB1177), and B.-T. B. and S.K. are grateful for support by the SFB1399 (Grant 413326622). R.T. was supported by the German Research Foundation (DFG) Grant 397659447. A.C.J. is supported by the German Research Foundation (DFG) Grant JO 1473/1-3. T.H. and S.K. are grateful for support by the ENABLE project "Unraveling mechanisms driving cellular homeostasis, inflammation and infection to enable new approaches in translational medicine". The CQ1 microscope was funded by FUGG (INST 161/920-1 FUGG). We want to thank Julia Frischkorn for her passionate cell culture work. Data collection at the Swiss Light Source (SLS) was supported by funding from the European Union's Horizon 2020 research and innovation program Grant 730872, project CALIPSOplus. We also thank the staff at SLS beamline X06SA for assistance during data collection. T.K., A.P. and E.S. would like to thank TuCAD2, which is funded by the Federal Ministry of Education and Research (BMBF) and the Baden-Wurttemberg Ministry of Science as part of the Excellence Strategy of the German Federal and State Governments EXC 2180-390900677. T.K. is supported by the Fortune initiative (no. 2613-0-0) and by the iFIT, which are both initiatives from the Excellence Strategy of the German Federal and State Governments. We thank CSC-Finland for the generous computational resources provided.